Effect of high-dose etodolac on renal function.
Previous studies from our laboratory have demonstrated transient effects on renal function by etodolac, 200 mg b.i.d. The current study assessed the effects of a larger dose of etodolac (500 mg b.i.d.) to explore the time course of its renal effects and to determine whether the transient effect would become more prolonged with a larger dose. We studied 10 normal subjects and nine patients with renal insufficiency, examining the effects of the first 500 mg dose of etodolac as well as 4 days of b.i.d. administration. In both groups, etodolac transiently decreased fractional excretions of sodium and chloride and urinary prostaglandin E2. In patients, etodolac also transiently decreased inulin and para-aminohippuric acid clearances and urinary 6-keto-prostaglandin F1 alpha. Chronic administration caused no changes in renal function in either group. In summary, in this relatively small group of patients, high-dose etodolac caused only transient, fully reversible effects on renal function, the cumulative effect of which was negligible.
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000085:Acetates / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D015232:Dinoprostone; D017308:Etodolac; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011458:Prostaglandins E / Q000652:urine; D012016:Reference Values; D012083:Renin / Q000097:blood; D012964:Sodium / Q000652:urine
D000085:Acetates; D000894:Anti-Inflammatory Agents, Non-Steroidal; D011458:Prostaglandins E; D017308:Etodolac; D000450:Aldosterone; D015121:6-Ketoprostaglandin F1 alpha; D012964:Sodium; D012083:Renin; D015232:Dinoprostone; D011188:Potassium